| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 29 | 2023 | 15694 | 1.950 |
Why?
|
| Antineoplastic Agents, Hormonal | 7 | 2022 | 840 | 1.500 |
Why?
|
| Receptors, G-Protein-Coupled | 4 | 2022 | 488 | 1.480 |
Why?
|
| Neoplastic Cells, Circulating | 4 | 2019 | 607 | 1.380 |
Why?
|
| Medication Adherence | 4 | 2023 | 492 | 1.250 |
Why?
|
| Oncogene Proteins | 2 | 2021 | 354 | 1.240 |
Why?
|
| Receptor, ErbB-2 | 9 | 2023 | 2518 | 1.200 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2015 | 749 | 0.980 |
Why?
|
| Receptors, Neuropeptide Y | 1 | 2022 | 6 | 0.850 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2022 | 42 | 0.830 |
Why?
|
| Receptors, Estrogen | 8 | 2020 | 2086 | 0.770 |
Why?
|
| Prescription Drugs | 2 | 2019 | 64 | 0.740 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2022 | 5178 | 0.730 |
Why?
|
| Receptors, Dopamine D1 | 3 | 2005 | 79 | 0.710 |
Why?
|
| Estrogen Receptor alpha | 2 | 2022 | 701 | 0.700 |
Why?
|
| Breast Neoplasms, Male | 1 | 2020 | 229 | 0.660 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 521 | 0.580 |
Why?
|
| Estrogen Antagonists | 2 | 2018 | 184 | 0.540 |
Why?
|
| Quinolines | 1 | 2019 | 383 | 0.530 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 470 | 0.530 |
Why?
|
| Febrile Neutropenia | 1 | 2015 | 65 | 0.520 |
Why?
|
| Kidney Tubules, Proximal | 3 | 2005 | 142 | 0.510 |
Why?
|
| Mucositis | 1 | 2015 | 148 | 0.510 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 10035 | 0.490 |
Why?
|
| Cancer Survivors | 2 | 2018 | 650 | 0.490 |
Why?
|
| Tamoxifen | 6 | 2022 | 876 | 0.490 |
Why?
|
| Glutamine | 1 | 2015 | 299 | 0.470 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 799 | 0.470 |
Why?
|
| Acneiform Eruptions | 1 | 2013 | 7 | 0.470 |
Why?
|
| Thiazolidinediones | 2 | 2005 | 148 | 0.460 |
Why?
|
| Antineoplastic Agents | 7 | 2019 | 14289 | 0.460 |
Why?
|
| Aromatase Inhibitors | 4 | 2020 | 305 | 0.440 |
Why?
|
| Cytotoxins | 1 | 2012 | 66 | 0.420 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2013 | 266 | 0.420 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2013 | 216 | 0.420 |
Why?
|
| Ketones | 1 | 2012 | 54 | 0.420 |
Why?
|
| Furans | 1 | 2012 | 104 | 0.410 |
Why?
|
| RANK Ligand | 1 | 2012 | 119 | 0.400 |
Why?
|
| Drug Eruptions | 1 | 2013 | 256 | 0.390 |
Why?
|
| Female | 33 | 2023 | 141928 | 0.380 |
Why?
|
| Quinazolines | 3 | 2015 | 923 | 0.360 |
Why?
|
| Heterografts | 4 | 2022 | 733 | 0.350 |
Why?
|
| Estradiol | 4 | 2022 | 748 | 0.330 |
Why?
|
| Tubulin Modulators | 1 | 2008 | 65 | 0.320 |
Why?
|
| Epothilones | 1 | 2008 | 54 | 0.320 |
Why?
|
| Cell Line, Tumor | 7 | 2022 | 14551 | 0.320 |
Why?
|
| Palliative Care | 1 | 2019 | 2037 | 0.310 |
Why?
|
| Humans | 39 | 2023 | 261506 | 0.300 |
Why?
|
| Obesity | 3 | 2023 | 2884 | 0.300 |
Why?
|
| Microtubules | 1 | 2008 | 270 | 0.300 |
Why?
|
| Estrogens | 3 | 2022 | 751 | 0.290 |
Why?
|
| Cell Membrane | 3 | 2005 | 850 | 0.290 |
Why?
|
| Postmenopause | 3 | 2023 | 378 | 0.280 |
Why?
|
| Dopamine | 2 | 2004 | 312 | 0.270 |
Why?
|
| Cell Proliferation | 5 | 2022 | 7226 | 0.260 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2005 | 43 | 0.260 |
Why?
|
| Mice | 11 | 2022 | 34495 | 0.260 |
Why?
|
| Animals | 15 | 2022 | 59536 | 0.250 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2004 | 40 | 0.240 |
Why?
|
| Administration, Oral | 2 | 2020 | 1544 | 0.240 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2004 | 132 | 0.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 15862 | 0.220 |
Why?
|
| Transplantation, Autologous | 3 | 2013 | 1914 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2023 | 198 | 0.210 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2021 | 35 | 0.200 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2009 | 6550 | 0.200 |
Why?
|
| Medicare | 2 | 2023 | 860 | 0.200 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 3890 | 0.190 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2009 | 1303 | 0.190 |
Why?
|
| Minority Groups | 1 | 2023 | 322 | 0.190 |
Why?
|
| G1 Phase | 1 | 2021 | 285 | 0.190 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2021 | 278 | 0.180 |
Why?
|
| Hyaluronan Receptors | 2 | 2018 | 249 | 0.180 |
Why?
|
| Polypharmacy | 1 | 2019 | 57 | 0.170 |
Why?
|
| Bone Neoplasms | 1 | 2012 | 2576 | 0.170 |
Why?
|
| Cinnamates | 1 | 2018 | 27 | 0.170 |
Why?
|
| Lung Neoplasms | 2 | 2019 | 11538 | 0.170 |
Why?
|
| Signal Transduction | 7 | 2021 | 11965 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 4367 | 0.170 |
Why?
|
| Thy-1 Antigens | 1 | 2018 | 51 | 0.170 |
Why?
|
| Leukocyte Common Antigens | 1 | 2019 | 188 | 0.160 |
Why?
|
| Metformin | 1 | 2022 | 378 | 0.160 |
Why?
|
| Aged | 9 | 2023 | 70117 | 0.160 |
Why?
|
| Graft vs Host Disease | 1 | 2009 | 2638 | 0.160 |
Why?
|
| Keratins | 1 | 2019 | 330 | 0.160 |
Why?
|
| Neoplasms | 2 | 2015 | 15193 | 0.150 |
Why?
|
| Treatment Outcome | 6 | 2019 | 32848 | 0.150 |
Why?
|
| Middle Aged | 10 | 2020 | 86204 | 0.150 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2018 | 342 | 0.150 |
Why?
|
| Purines | 1 | 2018 | 273 | 0.150 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 218 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2022 | 8873 | 0.150 |
Why?
|
| Transcriptome | 2 | 2016 | 1859 | 0.150 |
Why?
|
| Cell Separation | 1 | 2019 | 612 | 0.150 |
Why?
|
| Aminopyridines | 1 | 2018 | 212 | 0.150 |
Why?
|
| Receptors, Progesterone | 2 | 2020 | 1392 | 0.150 |
Why?
|
| Retrospective Studies | 5 | 2023 | 37905 | 0.150 |
Why?
|
| Mice, SCID | 2 | 2019 | 1869 | 0.140 |
Why?
|
| Atrophic Vaginitis | 1 | 2016 | 1 | 0.140 |
Why?
|
| Adult | 8 | 2020 | 77950 | 0.140 |
Why?
|
| RNA, Small Interfering | 3 | 2018 | 2216 | 0.140 |
Why?
|
| Metabolic Syndrome | 1 | 2020 | 353 | 0.140 |
Why?
|
| Rats | 4 | 2008 | 6086 | 0.140 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2016 | 65 | 0.140 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 332 | 0.140 |
Why?
|
| Mice, Nude | 2 | 2021 | 4307 | 0.140 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 29902 | 0.140 |
Why?
|
| Neoplasm Metastasis | 4 | 2018 | 5112 | 0.140 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 1519 | 0.130 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2015 | 34 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 3 | 2019 | 4975 | 0.130 |
Why?
|
| Transcription Factor AP-1 | 1 | 2016 | 246 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 1077 | 0.130 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 7222 | 0.130 |
Why?
|
| Carcinogenesis | 1 | 2021 | 1026 | 0.130 |
Why?
|
| Rats, Zucker | 2 | 2005 | 60 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2020 | 2292 | 0.130 |
Why?
|
| Neutropenia | 2 | 2009 | 968 | 0.120 |
Why?
|
| Colforsin | 2 | 2004 | 59 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2019 | 1234 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2018 | 3821 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 992 | 0.120 |
Why?
|
| Cancer Pain | 1 | 2019 | 312 | 0.120 |
Why?
|
| Interleukin-8 | 1 | 2016 | 519 | 0.120 |
Why?
|
| Pandemics | 1 | 2023 | 1559 | 0.120 |
Why?
|
| Mastectomy | 1 | 2020 | 1534 | 0.120 |
Why?
|
| Pain Management | 1 | 2019 | 668 | 0.120 |
Why?
|
| Hyperbilirubinemia | 1 | 2013 | 78 | 0.110 |
Why?
|
| Breast | 1 | 2020 | 1344 | 0.110 |
Why?
|
| Blood Component Removal | 1 | 2013 | 121 | 0.110 |
Why?
|
| Transplantation, Homologous | 2 | 2009 | 2843 | 0.110 |
Why?
|
| Indoles | 1 | 2018 | 1009 | 0.110 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 13658 | 0.110 |
Why?
|
| Electronic Health Records | 1 | 2020 | 929 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 1362 | 0.100 |
Why?
|
| Risk Factors | 4 | 2020 | 17523 | 0.100 |
Why?
|
| Endocrine System | 1 | 2011 | 36 | 0.100 |
Why?
|
| Taxoids | 1 | 2015 | 967 | 0.100 |
Why?
|
| Denosumab | 1 | 2012 | 68 | 0.100 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2011 | 112 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 2483 | 0.100 |
Why?
|
| Epithelial Cells | 1 | 2018 | 1818 | 0.100 |
Why?
|
| Male | 9 | 2020 | 123000 | 0.100 |
Why?
|
| Risk | 1 | 2015 | 1972 | 0.100 |
Why?
|
| Organoplatinum Compounds | 1 | 2013 | 702 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2015 | 2316 | 0.090 |
Why?
|
| Leukopoiesis | 1 | 2009 | 7 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 2330 | 0.090 |
Why?
|
| Registries | 1 | 2018 | 2170 | 0.090 |
Why?
|
| Filgrastim | 1 | 2009 | 191 | 0.090 |
Why?
|
| Blood Glucose | 2 | 2005 | 1244 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2015 | 1493 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 6009 | 0.090 |
Why?
|
| Ketoglutaric Acids | 1 | 2009 | 38 | 0.090 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 1371 | 0.090 |
Why?
|
| California | 1 | 2009 | 208 | 0.090 |
Why?
|
| Enzyme Inhibitors | 2 | 2009 | 1879 | 0.090 |
Why?
|
| Hospitals, University | 1 | 2009 | 209 | 0.090 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2009 | 46 | 0.090 |
Why?
|
| Depression | 1 | 2019 | 1715 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2012 | 621 | 0.090 |
Why?
|
| United States | 2 | 2023 | 15433 | 0.080 |
Why?
|
| Insulin Resistance | 2 | 2005 | 731 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2015 | 2218 | 0.080 |
Why?
|
| Drug Interactions | 1 | 2010 | 553 | 0.080 |
Why?
|
| Insulin | 2 | 2005 | 1454 | 0.080 |
Why?
|
| Cyclophosphamide | 1 | 2015 | 3001 | 0.080 |
Why?
|
| Biological Assay | 1 | 2009 | 177 | 0.080 |
Why?
|
| Young Adult | 3 | 2019 | 21445 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 2594 | 0.080 |
Why?
|
| Dogs | 1 | 2008 | 1155 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2008 | 566 | 0.070 |
Why?
|
| Structure-Activity Relationship | 1 | 2008 | 931 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2011 | 2074 | 0.070 |
Why?
|
| CD24 Antigen | 2 | 2018 | 85 | 0.070 |
Why?
|
| MCF-7 Cells | 2 | 2018 | 550 | 0.070 |
Why?
|
| G-Protein-Coupled Receptor Kinase 4 | 1 | 2005 | 2 | 0.070 |
Why?
|
| Recurrence | 1 | 2013 | 4758 | 0.060 |
Why?
|
| beta-Adrenergic Receptor Kinases | 1 | 2005 | 58 | 0.060 |
Why?
|
| Radioligand Assay | 1 | 2004 | 54 | 0.060 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2004 | 38 | 0.060 |
Why?
|
| Second Messenger Systems | 1 | 2004 | 39 | 0.060 |
Why?
|
| Microvilli | 1 | 2004 | 83 | 0.060 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2008 | 393 | 0.060 |
Why?
|
| Dopamine Antagonists | 1 | 2004 | 52 | 0.060 |
Why?
|
| Precipitin Tests | 1 | 2004 | 329 | 0.060 |
Why?
|
| Cytokines | 1 | 2013 | 2809 | 0.060 |
Why?
|
| Macrolides | 1 | 2004 | 62 | 0.060 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2005 | 234 | 0.060 |
Why?
|
| 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 1 | 2004 | 36 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2020 | 6869 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 1085 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 2927 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 1443 | 0.060 |
Why?
|
| Prognosis | 3 | 2019 | 21713 | 0.060 |
Why?
|
| Benzazepines | 1 | 2004 | 108 | 0.060 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 2004 | 134 | 0.060 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 591 | 0.060 |
Why?
|
| Urine | 1 | 2004 | 143 | 0.060 |
Why?
|
| Cyclic AMP | 1 | 2004 | 358 | 0.060 |
Why?
|
| Time Factors | 3 | 2015 | 12926 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2020 | 12873 | 0.060 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 3719 | 0.060 |
Why?
|
| GTP-Binding Proteins | 1 | 2004 | 321 | 0.060 |
Why?
|
| Length of Stay | 1 | 2009 | 1900 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 5159 | 0.050 |
Why?
|
| Sodium | 1 | 2004 | 353 | 0.050 |
Why?
|
| Protein Transport | 1 | 2004 | 734 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2012 | 2819 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 3251 | 0.050 |
Why?
|
| Waist Circumference | 1 | 2020 | 92 | 0.050 |
Why?
|
| Body Weight | 1 | 2005 | 1293 | 0.050 |
Why?
|
| Transplantation Conditioning | 1 | 2009 | 2238 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 2 | 2018 | 3101 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 10331 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2004 | 2063 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 2403 | 0.040 |
Why?
|
| Mutation | 1 | 2019 | 15179 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2005 | 1467 | 0.040 |
Why?
|
| Premenopause | 1 | 2018 | 131 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2004 | 3536 | 0.040 |
Why?
|
| Survival Rate | 1 | 2011 | 12221 | 0.040 |
Why?
|
| Apoptosis | 1 | 2012 | 7591 | 0.040 |
Why?
|
| Standard of Care | 1 | 2018 | 243 | 0.040 |
Why?
|
| Trastuzumab | 1 | 2019 | 696 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2005 | 4804 | 0.040 |
Why?
|
| Administration, Intravaginal | 1 | 2016 | 10 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 4557 | 0.040 |
Why?
|
| Receptor Cross-Talk | 1 | 2015 | 79 | 0.030 |
Why?
|
| Disease Progression | 2 | 2018 | 6682 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 14889 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 2314 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 2352 | 0.030 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2013 | 171 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 1313 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 792 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2022 | 6100 | 0.030 |
Why?
|
| Bilirubin | 1 | 2013 | 221 | 0.030 |
Why?
|
| Hepatic Artery | 1 | 2013 | 240 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2016 | 667 | 0.030 |
Why?
|
| Stem Cells | 1 | 2018 | 1213 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 1399 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2013 | 369 | 0.020 |
Why?
|
| Terfenadine | 1 | 2010 | 2 | 0.020 |
Why?
|
| Age Factors | 1 | 2020 | 5377 | 0.020 |
Why?
|
| Quinidine | 1 | 2010 | 16 | 0.020 |
Why?
|
| Survivors | 1 | 2016 | 1031 | 0.020 |
Why?
|
| Propanolamines | 1 | 2010 | 44 | 0.020 |
Why?
|
| Digoxin | 1 | 2010 | 63 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2018 | 2295 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2012 | 369 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2012 | 905 | 0.020 |
Why?
|
| Titrimetry | 1 | 2009 | 10 | 0.020 |
Why?
|
| Chemical Precipitation | 1 | 2009 | 23 | 0.020 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2009 | 82 | 0.020 |
Why?
|
| Succinic Acid | 1 | 2009 | 23 | 0.020 |
Why?
|
| Hydroxylation | 1 | 2009 | 65 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2009 | 52 | 0.020 |
Why?
|
| Adolescent | 1 | 2009 | 31252 | 0.020 |
Why?
|
| Cell Survival | 1 | 2015 | 3045 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2010 | 260 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2018 | 2669 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2009 | 549 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 10001 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 1756 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 1408 | 0.020 |
Why?
|
| Hydrazines | 1 | 2009 | 208 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 376 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 3570 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 2049 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2012 | 1996 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 9180 | 0.020 |
Why?
|
| Quality of Life | 1 | 2018 | 4532 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 5047 | 0.010 |
Why?
|
| Peptides | 1 | 2009 | 1479 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 4320 | 0.010 |
Why?
|
| Genotype | 1 | 2010 | 4109 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2009 | 1664 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 6295 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 4549 | 0.010 |
Why?
|